GoodRx Holdings, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx first quarter 2023 earnings call. As a reminder, today's conference is being recorded. I would now like to introduce your host for today's call, Aubrey Reynolds, senior manager of investor relations. Ms. Reynolds, you may begin.

Thank you, operator. Good afternoon, everyone, and welcome to GoodRx's earnings conference call for the first quarter 2023. Joining me today are Doug Hirsch, our Chief Mission Officer, Trevor Bezdek, our Chairman, Carson Vorman, our Chief Financial Officer, and Scott Wagner, our Interim Chief Executive Officer. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on the call that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding management's plans, strategies, goals, and objectives, our market opportunities, our anticipated financial performance, the impact of the grocery issue on our business, underlying trends in our business, our potential for growth, collaborations, and partnerships with third parties, and the expected impact from macroeconomic environment on our business. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors. These factors may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Factors discussed in the risk factors section of our annual report on Form 10-K for the year ended December 31st, 2022, As updated by our quarterly report on Form 10-Q for the quarter ended March 31st, 2023, and other filings with the Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any such forward-looking statements represents management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change. In addition, we may also reference non-GAAP metrics, which are reconciled to the nearest GAAP metrics in the company's earnings press release, which can be found on the overview page of the Investor Relations website at investors.gooderax.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well. With that, I'll turn it over to Doug.

Thank you, Aubrey. Good morning, everyone, and thank you for joining us. We started GoodRx 12 years ago because we were passionate about helping consumers access and afford the care they deserve. We are so proud that the company we built has become a service that millions of consumers rely on. Since those early days, much has changed, and our business has evolved into something bigger than Trevor and I ever dreamed. We have saved Americans over $55 billion on their medications, and our team has launched entirely new business lines, including pharma manufacturer solutions, which enables us to make brand drugs more accessible, and GoodRx Health, which we believe offers some of the best and most trusted online health content. It's been both exciting and rewarding to build a business that enables us to help even more people in more ways. Trevor and I love what we do, but we also recognize that an important part of expanding our impact includes generating growth, margins, and profitability. We've always known that there would be a time when there would be others better equipped than us to run and grow a large public company, and I'm proud to say that we've found that person in Scott Wagner, who's agreed to step in as our interim CEO. Scott brings more than 25 years of experience running and scaling consumer technology companies that are leaders in their field, including at public companies, and has the knowledge and expertise needed to enter the next phase of our company's growth. In 2012, Scott stepped in as interim CEO at GoDaddy and went on to become president, COO, CFO, and then CEO. During his tenure, he took the company public, nearly tripled revenue to approximately $3 billion, grew the business profitably, and managed over 7,000 employees. Scott also has experience working with our sponsors, Silver Lake, Francisco Partners, and Spectrum Equity. I've been working alongside him for the past two weeks and have already seen him put his breadth of experience into action. Trevor and I are excited about what Scott's new perspective will bring. It's no secret this past year has been rough. Our results have disappointed us as well as our stakeholders, and we believe the time is right to have someone lead the company who has extensive experience running and growing public companies. We truly feel this is just the beginning of what GoodRx can accomplish. We love GoodRx and want it to succeed more than anything else. Trevor and I are remaining at the company and are committed to supporting Scott and the business. I have taken on the role of Chief Mission Officer and am so excited that I get to focus on doing what I love most, evangelizing the company's mission to external parties Whether it's physicians, manufacturers, pharma, or other partners, I will spend my time talking about all the amazing ways we aim to make healthcare affordable and convenient for Americans. I will now pass the call over to Trevor.